MedTrace Logo

Olmesartan Medoxomil in Diabetes Mellitus

NCT00185159 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4449

Last updated 2010-01-20

No results posted yet for this study

Summary

This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.

Conditions

Interventions

DRUG

Olmesartan medoxomil

tablets

DRUG

Placebo Tablets

Tablets

Sponsors & Collaborators

  • Sankyo Pharma Gmbh

    lead INDUSTRY

Principal Investigators

  • Prof. Hermann Haller, MD · Medizinische Hochschule Hannover Klinik fur Nieren, Hannover Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185159 on ClinicalTrials.gov